185 related articles for article (PubMed ID: 20870592)
1. In vitro activity of conventional antifungal agents against Scedosporium apiospermum isolates recovered from clinical and environmental samples in Nigeria.
Nweze EI; Okafor JI
Acta Microbiol Immunol Hung; 2010 Sep; 57(3):209-14. PubMed ID: 20870592
[TBL] [Abstract][Full Text] [Related]
2. Activity of voriconazole against corneal isolates of Scedosporium apiospermum.
Shah KB; Wu TG; Wilhelmus KR; Jones DB
Cornea; 2003 Jan; 22(1):33-6. PubMed ID: 12502945
[TBL] [Abstract][Full Text] [Related]
3. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates.
Meletiadis J; Meis JF; Mouton JW; Rodriquez-Tudela JL; Donnelly JP; Verweij PE;
Antimicrob Agents Chemother; 2002 Jan; 46(1):62-8. PubMed ID: 11751112
[TBL] [Abstract][Full Text] [Related]
4. Antifungal susceptibilities of the species of the Pseudallescheria boydii complex.
Gilgado F; Serena C; Cano J; Gené J; Guarro J
Antimicrob Agents Chemother; 2006 Dec; 50(12):4211-3. PubMed ID: 17015631
[TBL] [Abstract][Full Text] [Related]
5. Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum.
Cuenca-Estrella M; Ruiz-Díez B; Martínez-Suárez JV; Monzón A; Rodríguez-Tudela JL
J Antimicrob Chemother; 1999 Jan; 43(1):149-51. PubMed ID: 10381115
[TBL] [Abstract][Full Text] [Related]
6. Chronic airway colonization by Scedosporium apiospermum with a fatal outcome in a patient with cystic fibrosis.
Borghi E; Iatta R; Manca A; Montagna MT; Morace G
Med Mycol; 2010 Nov; 48 Suppl 1():S108-13. PubMed ID: 21067322
[TBL] [Abstract][Full Text] [Related]
7. Molecular identification and in vitro antifungal susceptibility of Scedosporium complex isolates from high-human-activity sites in Mexico.
Elizondo-Zertuche M; de J Treviño-Rangel R; Robledo-Leal E; Luna-Rodríguez CE; Martínez-Fierro ML; Rodríguez-Sánchez IP; González GM
Mycologia; 2017; 109(6):874-881. PubMed ID: 29494271
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility of Pseudallescheria boydii and Scedosporium apiospermum to new antifungal agents.
Zeng J; Kamei K; Zheng Y; Nishimura K
Nihon Ishinkin Gakkai Zasshi; 2004; 45(2):101-4. PubMed ID: 15118667
[TBL] [Abstract][Full Text] [Related]
9. Scedosporium apiospermum keratitis treated with itraconazole.
Saracli MA; Erdem U; Gonlum A; Yildiran ST
Med Mycol; 2003 Apr; 41(2):111-4. PubMed ID: 12964842
[TBL] [Abstract][Full Text] [Related]
10. In vitro activities of 35 double combinations of antifungal agents against Scedosporium apiospermum and Scedosporium prolificans.
Cuenca-Estrella M; Alastruey-Izquierdo A; Alcazar-Fuoli L; Bernal-Martinez L; Gomez-Lopez A; Buitrago MJ; Mellado E; Rodriguez-Tudela JL
Antimicrob Agents Chemother; 2008 Mar; 52(3):1136-9. PubMed ID: 18195067
[TBL] [Abstract][Full Text] [Related]
11. Lymphadenitis caused by Scedosporium apiospermum in an immunocompetent patient.
Kiraz N; Gülbas Z; Akgün Y; Uzun O
Clin Infect Dis; 2001 Feb; 32(3):E59-61. PubMed ID: 11170973
[TBL] [Abstract][Full Text] [Related]
12. Assessing micafungin/triazole combinations for the treatment of invasive scedosporiosis due to Scedosporium apiospermum and Scedosporium boydii.
Lackner M; Fernández-Silva F; Guarro J; Lass-Flörl C
J Antimicrob Chemother; 2014 Nov; 69(11):3027-32. PubMed ID: 24986494
[TBL] [Abstract][Full Text] [Related]
13. Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species.
Lackner M; de Hoog GS; Verweij PE; Najafzadeh MJ; Curfs-Breuker I; Klaassen CH; Meis JF
Antimicrob Agents Chemother; 2012 May; 56(5):2635-42. PubMed ID: 22290955
[TBL] [Abstract][Full Text] [Related]
14. In vitro activities of four novel triazoles against Scedosporium spp.
Carrillo AJ; Guarro J
Antimicrob Agents Chemother; 2001 Jul; 45(7):2151-3. PubMed ID: 11408242
[TBL] [Abstract][Full Text] [Related]
15. In vitro synergistic interaction between amphotericin B and micafungin against Scedosporium spp.
Yustes C; Guarro J
Antimicrob Agents Chemother; 2005 Aug; 49(8):3498-500. PubMed ID: 16048969
[TBL] [Abstract][Full Text] [Related]
16. Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy.
Muñoz P; Marín M; Tornero P; Martín Rabadán P; Rodríguez-Creixéms M; Bouza E
Clin Infect Dis; 2000 Dec; 31(6):1499-501. PubMed ID: 11096022
[TBL] [Abstract][Full Text] [Related]
17. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.
Espinel-Ingroff A
J Clin Microbiol; 2001 Mar; 39(3):954-8. PubMed ID: 11230410
[TBL] [Abstract][Full Text] [Related]
18. [The Importance of Mycological Diagnosis: A Scedosporium apiospermum Complex Mycetoma Case Neglected For 20 Years].
Barış A; Öncül A; Öztürk K; Barış A; Aykut S; Aktaş E
Mikrobiyol Bul; 2021 Apr; 55(2):256-264. PubMed ID: 33882656
[TBL] [Abstract][Full Text] [Related]
19. Septic arthritis due to Scedosporium apiospermum: case report and review.
Tirado-Miranda R; Solera-Santos J; Brasero JC; Haro-Estarriol M; Cascales-Sánchez P; Igualada JB
J Infect; 2001 Oct; 43(3):210-2. PubMed ID: 11798262
[TBL] [Abstract][Full Text] [Related]
20. In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp.
Lewis RE; Wiederhold NP; Klepser ME
Antimicrob Agents Chemother; 2005 Mar; 49(3):945-51. PubMed ID: 15728887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
